Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1983 Jan;46(1):14–17. doi: 10.1136/jnnp.46.1.14

Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseases.

J Sundquist, M L Forsling, J E Olsson, M Akerlund
PMCID: PMC1027257  PMID: 6842195

Abstract

Arginine vasopressin (AVP) was determined in plasma and lumbar CSF from 46 patients with Parkinson's disease, dementia, cerebrovascular disease, multiple sclerosis and other, mostly peripheral neurological disorders. The mean plasma concentration of AVP was 1.62 microU/ml, the CSF concentration 1.14 microU/ml and the gradient CSF/plasma 0.72. There was a good correlation between the plasma and the CSF values in most patients. No sex difference could be found. A slight decrease of the CSF values could be found with increasing age. Significantly higher CSF-AVP values were found in patients with cerebrovascular disease, whereas lower CSF values were found in patients with dementia and Parkinson's disease. However there were decreased CSF/plasma gradients in patients with dementia and Parkinson's disease to about 0.30 compared to 0.98 in patients with peripheral neurological disorders. Patients with multiple sclerosis had an increased IgG index indicating an intrathecal IgG production but there was no obvious correlation between this and the AVP concentrations in plasma and CSF, nor with the total CSF protein content, nor with the albumin and IgG concentrations in plasma and CSF.

Full text

PDF
14

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akerlund M., Strömberg P., Forsling M. L. Primary dysmenorrhoea and vasopressin. Br J Obstet Gynaecol. 1979 Jun;86(6):484–487. doi: 10.1111/j.1471-0528.1979.tb10794.x. [DOI] [PubMed] [Google Scholar]
  2. Ang V. T., Jenkins J. S. Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog. J Endocrinol. 1982 Jun;93(3):319–325. doi: 10.1677/joe.0.0930319. [DOI] [PubMed] [Google Scholar]
  3. Garcia H., Kaplan S. L., Feigin R. D. Cerebrospinal fluid concentration of arginine vasopressin in children with bacterial meningitis. J Pediatr. 1981 Jan;98(1):67–70. doi: 10.1016/s0022-3476(81)80537-9. [DOI] [PubMed] [Google Scholar]
  4. Heller H., Hasan S. H., Saifi A. Q. Antidiuretic activity in the cerebrospinal fluid. J Endocrinol. 1968 Jun;41(2):273–280. doi: 10.1677/joe.0.0410273. [DOI] [PubMed] [Google Scholar]
  5. Jenkins J. S., Mather H. M., Ang V. Vasopressin in human cerebrospinal fluid. J Clin Endocrinol Metab. 1980 Feb;50(2):364–367. doi: 10.1210/jcem-50-2-364. [DOI] [PubMed] [Google Scholar]
  6. Jensen J. P. Vasopressin therapy in Parkinson's disease. Acta Neurol Scand. 1980 Sep;62(3):197–199. doi: 10.1111/j.1600-0404.1980.tb03024.x. [DOI] [PubMed] [Google Scholar]
  7. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  8. Lightman S. L., Forsling M. Evidence for dopamine as an inhibitor of vasoprotein release in man. Clin Endocrinol (Oxf) 1980 Jan;12(1):39–46. doi: 10.1111/j.1365-2265.1980.tb03130.x. [DOI] [PubMed] [Google Scholar]
  9. Mather H. M., Ang V., Jenkins J. S. Vasopressin in plasma and CSF of patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1981 Mar;44(3):216–219. doi: 10.1136/jnnp.44.3.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Olsson J. E., Pettersson B. A comparison between agar gel electrophoresis and CSF serum quotients of IgG and albumin in neurological disease. Acta Neurol Scand. 1976 Apr;53(4):308–322. doi: 10.1111/j.1600-0404.1976.tb04350.x. [DOI] [PubMed] [Google Scholar]
  11. Reid A. C., Morton J. J. Arginine vasopressin levels in cerebrospinal fluid in neurological disease. J Neurol Sci. 1982 May;54(2):295–301. doi: 10.1016/0022-510x(82)90190-3. [DOI] [PubMed] [Google Scholar]
  12. SCHUMACHER G. A., BEEBE G., KIBLER R. F., KURLAND L. T., KURTZKE J. F., MCDOWELL F., NAGLER B., SIBLEY W. A., TOURTELLOTTE W. W., WILLMON T. L. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x. [DOI] [PubMed] [Google Scholar]
  13. Strömberg P., Forsling M. L., Akerlund M. Effects of prostaglandin inhibition on vasopressin levels in women with primary dysmenorrhea. Obstet Gynecol. 1981 Aug;58(2):206–208. [PubMed] [Google Scholar]
  14. Tsuji M., Takahashi S., Akazawa S. CSF Vasopressin and cyclic nucleotide concentrations in senile dementia. Psychoneuroendocrinology. 1981;6(2):171–176. doi: 10.1016/0306-4530(81)90009-3. [DOI] [PubMed] [Google Scholar]
  15. Vorherr H., Bradbury M. W., Hoghoughi M., Kleeman C. R. Antidiuretic hormone in cerebrospinal fluid during endogenous and exogenous changes in its blood level. Endocrinology. 1968 Aug;83(2):246–250. doi: 10.1210/endo-83-2-246. [DOI] [PubMed] [Google Scholar]
  16. de Wied D. Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments. Life Sci. 1976 Sep 1;19(5):685–690. doi: 10.1016/0024-3205(76)90165-x. [DOI] [PubMed] [Google Scholar]
  17. van Ree J. M., Bohus B., Versteeg D. H., de Wied D. Neurohypophyseal principles and memory processes. Biochem Pharmacol. 1978;27(14):1793–1800. doi: 10.1016/0006-2952(78)90021-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES